Eli Lilly investors and analysts said they want to hear details from the company on how exactly it plans to grow U.S. sales ...

Eli Lilly (LLY) investors should expect fireworks this week as the pharma giant prepares to drop its bombshell Q4 2024 earnings figures before ...

Eli Lilly is set to report fourth-quarter earnings early Thursday, with analysts expecting rising sales and profit in the first full quarter with the company's weight-loss drugs no longer in shortage.

We recently published an article titled Jim Cramer’s Game Plan: 15 Stocks in Focus. In this article, we are going to take a ...

Truist raised the firm’s price target on Eli Lilly (LLY) to $1,038 from $1,029 and keeps a Buy rating on the shares. The firm is updating its ...

Keith Ellison said he's reached a deal with Danish pharmaceutical company Novo Nordisk to keep the cost of insulin at $35 a ...

Stocks closed the week slightly higher after Monday’s sell-off prompted by concerns over China’s DeepSeekopen-source API. In fact, the tech-heavy NASDAQ index was on pace to be the best-performing ...

In 2021, the FDA approved a new insulin drug, Semglee, that was interchangeable with a brand-name insulin called Lantus. Lantus cost $292 for a 30-day supply. Drugmaker Viatris launched two versions ...

CNBC's Jim Cramer on Friday walked investors through an earnings-heavy week, highlighting reports from Amazon, Alphabet, Eli ...

The IRA measure is a good first step, but some are looking even further ahead to GLP-1 price drops to increase access.

As more United States drug price changes have come to light this month, it remains clear that companies are tamping down ...